Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The identification of cancer-promoting genetic alterations is challenging particularly in highly unstable and heterogeneous cancers, such as esophageal adenocarcinoma (EAC). Here we describe a machine learning algorithm to identify cancer genes in individual patients considering all types of damaging alterations simultaneously. Analysing 261 EACs from the OCCAMS Consortium, we discover helper genes that, alongside well-known drivers, promote cancer. We confirm the robustness of our approach in 107 additional EACs. Unlike recurrent alterations of known drivers, these cancer helper genes are rare or patient-specific. However, they converge towards perturbations of well-known cancer processes. Recurrence of the same process perturbations, rather than individual genes, divides EACs into six clusters differing in their molecular and clinical features. Experimentally mimicking the alterations of predicted helper genes in cancer and pre-cancer cells validates their contribution to disease progression, while reverting their alterations reveals EAC acquired dependencies that can be exploited in therapy.

Original publication

DOI

10.1038/s41467-019-10898-3

Type

Journal article

Journal

Nature communications

Publication Date

15/07/2019

Volume

10

Addresses

Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.

Keywords

Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Humans, Adenocarcinoma, Esophageal Neoplasms, Disease Progression, Genomic Instability, Antineoplastic Agents, Gene Expression Profiling, Computational Biology, Gene Expression Regulation, Neoplastic, Gene Dosage, Polymorphism, Single Nucleotide, Multigene Family, Models, Genetic, Mutation Rate, Datasets as Topic, Machine Learning, Biomarkers, Tumor, Precision Medicine